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Background: Induced pluripotent stem cells (iPSCs) derived from somatic cells have enormous potential for clinical
applications. Notably, it was recently reported that reprogramming from somatic cells to iPSCs can induce genomic
copy number variation (CNV), which is one of the major genetic causes of human diseases. However it was unclear
if this genome instability is dependent on reprogramming methods and/or the genetic background of donor cells.
Furthermore, genome-wide CNV analysis is technically challenging and CNV data need to be interpreted with care.
Results: In order to carefully investigate the possible CNV instability during somatic reprogramming, we performed
genome-wide CNV analyses with 41 mouse iPSC lines generated from the same parental donor; therefore, the
donor’s genetic background can be controlled. Different reprogramming factor combinations and dosages were
used for investigating potential method-dependent effects on genome integrity. We detected 63 iPSC CNVs using
high-resolution comparative genomic hybridization. Intriguingly, CNV rates were negatively associated with the
dosages of classic factor(s). Furthermore, the use of high-performance engineered factors led to less CNVs than the
classic factor(s) of the same dosage.
Conclusion: Our observations suggest that sufficient reprogramming force can protect the genome from CNV
instability during the reprogramming process.
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Induced pluripotent stem cells (iPSCs), which are derived
from somatic cells through reprogramming via several
methods [1], have enormous numbers of potential applica-
tions, particularly in regenerative medicine, disease model-
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stated.reprogramming methods remain to be described for produ-
cing high-quality iPSCs [3]. Before developing personalized
stem cell therapies, genome integrity and other safety con-
cerns of iPSC technology must be addressed [4], particu-
larly as genome stability can have profound effects on
pluripotency, differentiation and the tumorigenicity of
resulting iPSCs [5]. Notably, it was recently shown that the
process of reprogramming somatic cells to iPSCs could in-
duce genome alterations such as copy number variation
(CNV) [6-8]. Current evidence suggests that these
reprogramming-associated CNVs could be either de novo
mutations or enriched mosaic variations in donor cells
[9,10]. CNVs are one of the major genetic causes of human
diseases [11]; therefore, it is imperative to carefully investi-
gate possible CNV instability during somatic reprogram-
ming before using iPSCs in a clinical or therapeutic setting.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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and the CNV data need to be interpreted with caution
[11,12]. To date, several genome technologies have been
utilized for genomic CNV analysis [12]; however, the fol-
lowing points need to be taken into consideration before
confirming CNV instability in iPSCs. Firstly, technical limi-
tations exist for identifying CNVs accurately, as the CNV
calls of SNP microarrays (SNP for single nucleotide poly-
morphism) are highly dependent on the external reference
set used for the analysis [12]. The lack of internal refer-
ences on SNP microarrays can lead to low signal-to-noise
ratios in the process of CNV calling whilst CNV data
obtained by comparative genomic hybridization (CGH)
technology are more reliable [12]. Secondly, previous CNV
calls in iPSCs cannot readily distinguish between
reprogramming-associated CNVs (either de novo CNV or
selected mosaic CNV) [10,13] and pre-existing germ-line
CNVs in parental cells. Finally, it is still unknown whether
the reported CNV instability is dependent on reprogram-
ming methods or due to the genetic backgrounds of paren-
tal cells [6,14], which can potentially cause method-specific
or donor-specific genome instability.
Considering the above concerns, we addressed the issue
of CNV instability in iPSCs by taking into account the fol-
lowing factors in our study design. Mouse iPSCs (miPSCs)
were generated from the same parental donor to exclude
the effect of the genetic background. Various combina-
tions of reprogramming factors and dosages were used for
CNV comparison between reprogramming methods. In
addition, a high-density CGH microarray assay comparing
miPSCs with their parental donor cells was used for
genome-wide screening for the CNVs associated with cell
reprogramming (Figure 1). Intriguingly, our observations
revealed the dosage effect of pluripotent factors on gen-
ome integrity during somatic reprogramming.
Results
Initially, we obtained 16 miPSC lines with the three
“Yamanaka” factors (Oct4/Klf4/Sox2, OKS) [15,16] and sin-
gle Oct4 [17] (Additional file 1): eight miPSC lines ob-
tained by O_0.5, the other eight lines obtained by
OKS_1.5. The dosage of each factor in these two methods
was equivalent. Intriguingly, we identified 24 CNVs in
eight miPSC lines of O_0.5 (i.e. 3.0 CNV/miPSC) and
seven CNVs in eight lines of OKS_1.5 (i.e. approximately
0.9 CNV/miPSC) (Additional file 2). The rates of miPSC
CNVs between these two reprogramming methods are ob-
viously different, suggesting that the strength of the iPSC
reprogramming has an effect on genome integrity. Poten-
tially this suggests that reduced diversity of reprogram-
ming factors and/or reduced reprogramming dosages may
induce more CNVs during somatic reprogramming.
To further investigate the possible roles of reprogram-
ming factor diversity and/or dosage in CNV instability,we generated another three sets of miPSC lines from the
same donor but using different factor combinations and
low/high (i.e., 0.5 ml/1.5 ml) dosages (see Methods for
details) (Additional file 1): five miPSC lines obtained by
O_1.5, ten lines obtained by OKS_0.5, and ten lines ob-
tained by engineered factors XYZK_0.5 [18]. Using CGH
assay we compared the resulting miPSC genomes with
their parental genomes and identified zero CNVs in five
miPSC lines of O_1.5 (i.e. 0 CNV/miPSC), 25 CNVs in
ten OKS_0.5 lines (i.e. 2.5 CNV/miPSC), and seven CNVs
in ten XYZK_0.5 lines (i.e. 0.7 CNV/miPSC) (Additional
file 2). In total, we screened the genomes of 41 miPSC
lines and identified 63 CNVs across 24 genomic loci of the
mouse genome (Figure 2 and Additional file 2).
To investigate the potential mechanism involved in
genome instability of miPSCs, we compared the CNV
rates between the various methods using the same repro-
gramming factor combinations with altered dosages. The
Mann–Whitney U test with the exact significance was
used for single-factor test and the ANOVA test was used
for two-factor test. By comparing the CNV numbers be-
tween O_0.5 and O_1.5 miPSC lines, we observed more
CNVs in O_0.5 miPSCs (24 CNVs/8 miPSCs) than in
O_1.5 miPSCs (0 CNV/5 miPSCs). This difference is sta-
tistically significant (p-value = 0.030, Mann–Whitney U
test) (Figure 3A). Similarly comparing the number of
CNVs in OKS_0.5 (25 CNVs/10 miPSCs) and OKS _1.5
miPSC lines (7 CNVs/8 miPSCs), although not significant
(p-value = 0.146, Mann–Whitney U test; Figure 3B) does
still suggest that a low dosage of reprogramming factors
may induce more CNVs than a high dosage. We also com-
bined the CNV data in Figure 3A and 3B together based
on their dosages. In the low dosage group (0.5 ml), 49
CNVs were detected in 18 miPSC lines (i.e. approximately
2.7 CNV/miPSC); while in the high dosage group (1.5 ml),
eight CNVs were detected in 13 miPSC lines (i.e. ap-
proximately 0.6 CNV/miPSC). A significant difference
in CNV rates was observed (p-value = 0.008, ANOVA
test) (Figure 3C), which strongly supports that the dose
of reprograming factors and consequently the repro-
gramming force can significantly affect the genome in-
stability during reprogramming, with higher doses and
stronger reprogramming providing a protective effect.
Notably, recent studies have reported that reprogram-
ming factor dosage can affect the epigenetic properties
of iPSCs [3] and increased levels of Oct4 and Klf4 were
observed to give rise to high-quality iPSCs [19,20].
To further explore the roles of reprogramming force in
CNV instability of miPSCs, we compared CNV rates be-
tween diverse factor-combinations, while their total dosages
remained the same. We introduced the engineered factors
XYZK (Oct4-VP16, Sox2-VP16, Klf4 and Nanog-VP16) due
to their strong promoting capability during reprogramming
[18]. The CNV rates are: O_0.5 (24 CNVs/8 miPSCs),
Figure 1 The experimental flow of genome-wide CNV analyses in miPSCs using high-density CGH microarrays. A total of 41 miPSC lines
were derived from the same donor of MEF B2 using different reprogramming factors and/or dosages. Genomic DNAs of the parental MEF B2 and
various miPSC lines were respectively extracted and fragmented. Cy5-dUTP was used for labeling miPSC DNAs and Cy3-dUTP for the donor DNAs.
Each labeled miPSC DNA was hybridized together with a labeled donor DNA onto the mouse genome CGH microarrays. Microarray handling and
data analysis were conducted following the Agilent oligonucleotide CGH protocol. Examples were shown for a copy number loss (deletion;
depicted by green concave) and a copy number gain (duplication; depicted by red convex) at the bottom.
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10 miPSCs) (Additional file 2). There is no significant dif-
ference between O_0.5 and OKS_0.5 (p-value = 0.633),
however, the CNVs of XYZK_0.5 are significantly less
than those in O_0.5 (p-value = 0.043) and those in
OKS_0.5 (p-value = 0.023) (Figure 3D). Particularly im-
portant was the observation that all the seven CNVs de-
tected in XYZK_0.5 came from just two of the ten iPSClines and six of those seven CNVs were in a single iPSC
line. The remaining eight iPSC lines of XYZK_0.5 ad
zero CNVs (Additional file 2). This suggests that high-
performance engineered factors XYZK are likely to help
maintain the genome integrity by reducing reprogram-
ming barriers. Consistently, these observations also sup-
port that sufficient reprogramming force has a positive
role in iPSC genome integrity.
1 2 3 54 76 98 1110
12 X18 191713 14 15 16 Y
Figure 2 The genome distribution of 24 loci of the miPSC CNVs identified in this study was shown. The green bars indicate the deletion
loci, and the red bars represent duplication loci.
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Mouse iPSCs were first generated by retroviral trans-
duction of four transcription factors: Oct3/4, Sox2, Klf4
and c-Myc [1]. However, reactivation of c-Myc increases
tumorigenicity in the chimeras, hindering clinical appli-
cations [21]. It was observed that the mice derived from
c-Myc-free iPSCs showed a significantly reduced inci-
dence of tumorigenicity compared with those derived by
the four classic factors [16]. For the sake of high-quality
iPSCs generation, we excluded c-Myc in our study de-
sign. Considering the low-efficiency of iPSCs induction
without c-Myc, we also utilized the optimized repro-
gramming culture conditions with ultra-high efficiency
on iPSCs generation [15].
Based on the reliable CGH technology, we found that
reprogramming factor dosage is negatively associated with
CNV rate. This result showed the possibility that sufficientreprogramming force may help maintain genome integrity
during somatic reprogramming.
Since the reprogramming process is an artificial process
that reverses the somatic cell fate into a pluripotent state,
reprogramming faces various epigenetic barriers that were
set during normal differentiation [3]. Previous evidence
showed that the reprogramming process can broadly be
divided into two phases: a long stochastic phase of gene
activation and a shorter, hierarchical, more deterministic
phase of gene activation [3]. The stochastic nature of the
reprogramming process suggests that not genetic but epi-
genetic barriers can be seen as roadblocks in the journey
to pluripotency [22]. Reprogramming factors initiate tran-
scriptional effect as well as epigenetic regulation to help
re-establishing pluripotency [23,24]. Moreover, some regu-
lators or chemicals, such as Jhdm1b, valporic acid and
vitamin C, can overcome these epigenetic barriers and so
C D
A B
Figure 3 Comparison of CNV rates between the miPSCs induced by different reprogramming methods. (A) The comparison of CNV
numbers between O_0.5 and O_1.5 miPSC lines. This difference is statistically significant (p-value = 0.030, Mann–Whitney U test with the exact
significance). (B) The comparison of CNV numbers between OKS_0.5 and OKS_1.5 miPSC lines (Mann–Whitney U test with the exact significance).
(C) The combinational analysis of (A) and (B). A significant difference of CNV numbers between high and low reprogramming factor dosages
was found (p-value = 0.008, ANOVA test for two-factor analysis). (D) The comparison of CNV numbers between the methods using diverse
reprogramming factors with balanced dosages (Mann–Whitney U test with the exact significance). The CNVs are significantly less in the miPSCs
of XYZK_0.5 than in those of O_0.5 (p-value = 0.043) and OKS_0.5 (p-value = 0.023).
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servations suggest that the strength of reprogramming
targeting epigenetic barriers is important for successful
reprogramming. On the other hand, the iPSCs derived
from the stochastic reprogramming phase represent the
cells experiencing greater epigenetic changes from the
somatic state to a pluripotent one, which could be recog-
nized as a kind of pressure. CNV instability investigated in
this study may serve as pressure-induced factors that take
part in overcoming epigenetic roadblocks. Therefore, we
suggest that iPSCs might experience more genome in-
stability during the reprogramming process if the strength
of reprogramming is not enough. Conversely, sufficient re-
programming force will lead to much fewer CNVs. Never-
theless, this hypothesis should be investigated further.
In total we performed genome-wide CNV analyses on
41 miPSC lines derived by different reprogramming fac-
tors and/or dosages and detected 63 miPSC CNVs. Theaverage CNV rate is approximately 1.5 per miPSC line,
which suggests that the CNVs associated with cell repro-
gramming is not frequent. The choices of appropriate
reprogramming methods with sufficient reprogramming
force are likely to help maintain genome integrity of
iPSCs.Conclusions
In summary, we showed, using the CGH microarray assay
to directly compare the CNV status of miPSCs to their
parental cells is reliable to identify CNV alterations associ-
ated with cell reprogramming. Based on the genome-wide
analyses of 41 miPSC lines derived by different methods,
we suggest that increasing factor dosages, or using high-
performance engineered factors [18], is beneficial for the
genome integrity of the resulting miPSCs. Our observa-
tions highlight the importance of further investigations on
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their effects on iPSC genome integrity.
Methods
Mouse iPSCs generated from the same donor
An embryonic fibroblast cell line (MEF B2) derived from
the OG2 mouse was used as the parental donor. The
donor cells were infected with retroviruses carrying the
indicated reprogramming factors for two days, and then
were cultured in iCD1 medium for the generation of
iPSCs [15]. We normalized the virus with equal titer
(low dosage, MOI = 15 when 0.5 ml virus was used; high
dosage, MOI = 45 when 1.5 ml virus was used) according
to the titer detecting by Takara Retrovirus Titer Set. In
total, we obtained eight miPSC lines using single-factor
Oct4 (0.5 ml Oct4, i.e. O_0.5), five lines using single-
factor Oct4 (1.5 ml Oct4, i.e. O_1.5), ten lines using
three-factor combination (0.167 ml Oct4, 0.167 ml Klf4,
and 0.167 ml Sox2, i.e. OKS_0.5), eight lines using three-
factor combination (0.5 ml Oct4, 0.5 ml Klf4, and 0.5 ml
Sox2, i.e. OKS_1.5), and ten lines obtained by previously
reported engineered factors (0.125 ml Oct4-VP16 (X),
0.125 ml Sox2-VP16 (Y), 0.125 ml Nanog-VP16 (Z) and
0.125 ml Klf4, i.e. XYZK_0.5) [18]. The reprogramming
efficiencies of different factor combinations were de-
scribed in previous studies [15,17,18]. The iPSC colonies
were picked based on Oct4-GFP expression and were
validated with a normal karyotype. All of the 41 miPSC
lines were harvested at passage 4 for further analysis. All
the miPSCs were maintained in mES2i medium, i.e.
DMEM supplemented with 15% (v/v) fetal bovine serum,
glutamine, non-necessary amino acid, 1000U/ml LIF,
1 μM PD0325901 and 3 μM Chir99021. Our experiments
performed with animals were approved by the relevant in-
stitutional animal care and use committee (IACUC) of
Guangzhou Institutes of Biomedicine and Health (GIBH).
High-resolution assay of comparative genomic
hybridization microarray
Genomic DNAs extracted from each miPSC line and the
parental donor (MEF B2) were fragmented using AluI and
RsaI enzyme digestion. DNA labeling was conducted using
Agilent SureTag DNA Labeling Kit. Different fluorescence
dyes were used for DNA labeling of miPSCs (Cy5-dUTP)
and the donor parental cell line (Cy3-dUTP). Each labeled
miPSC DNA was hybridized together with the labeled
donor DNA onto Agilent SurePrint G3 mouse 1 × 1 M
microarray for 40 hours at 65°C. DNA processing, micro-
array handling and scanning were conducted following the
Agilent oligonucleotide CGH protocol (version 6.0).
Genome-wide CNV analyses
The microarray scanning profiles were processed by
Agilent Feature Extraction 10.7.3.1. The extracted datawas analyzed and plotted by Agilent Workbench 7.0.
ADM-2 was selected as statistical algorithm with the
threshold of 6.0 and the Fuzzy Zero turning on. Each
CNV was called by at least four consecutive probes with
log2Ratio (fluorescence value ratio of miPSC-associated
Cy5 to donor-associated Cy3) consistent with deletion
or duplication.
Statistical analysis
The Mann–Whitney U test with the exact significance was
used to determine statistically significant differences in
miPSC CNVs between different reprogramming methods.
The ANOVA test was used in Figure 3C when a two-factor
test is needed. Differences were considered statistically sig-
nificant when p-value < 0.05.
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Additional file 1: Sample information of mouse iPSC lines.
Additional file 2: The CNVs identified in mouse iPSC linse.
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